Literature DB >> 31414239

Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial Impacts.

Sarah G Mitchell1,2, Bojana Pencheva1,2, Christopher C Porter3,4.   

Abstract

PURPOSE OF REVIEW: Germline genetic variants contribute to a substantial proportion of cases of cancer in childhood. The purpose of this review is to describe two emerging pediatric cancer predisposition syndromes, including published surveillance protocols, as well as the psychological impacts related to childhood cancer predisposition. RECENT
FINDINGS: DICER1 syndrome is pleotropic, predisposing to a variety of tumors and likely phenotypically broader than currently realized. Rhabdoid tumor predisposition syndrome carries a risk for development of aggressive malignancies occurring in nearly any tissue. New pediatric hereditary cancer syndromes are likely to be identified as genetic evaluation evolves. Advantages and disadvantages of genetic testing and surveillance protocols need to be discussed with patients and families in a team-based approach, with the input of a genetic counselor holding expertise in pediatric cancer predisposition. Finally, literature on psychosocial impacts of hereditary cancer syndromes in pediatric patients is sparse, necessitating further research.

Entities:  

Keywords:  Cancer predisposition; DICER1; Rhabdoid tumor predisposition; SMARCA4; SMARCB1; Surveillance

Mesh:

Year:  2019        PMID: 31414239     DOI: 10.1007/s11912-019-0836-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  54 in total

Review 1.  Defining and redefining the scope and goals of genetic counseling.

Authors:  Robert G Resta
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-11-15       Impact factor: 3.908

2.  Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors.

Authors:  J Savla; T T Chen; N R Schneider; C F Timmons; O Delattre; G E Tomlinson
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

3.  Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor.

Authors:  J A Biegel; B Fogelgren; L M Wainwright; J Y Zhou; H Bevan; L B Rorke
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

4.  Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers.

Authors:  N Sévenet; E Sheridan; D Amram; P Schneider; R Handgretinger; O Delattre
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

Review 5.  Hereditary cancers in children and ethical and psychosocial implications.

Authors:  D J MacDonald; M Lessick
Journal:  J Pediatr Nurs       Date:  2000-08       Impact factor: 2.145

6.  Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor.

Authors:  Gail E Tomlinson; Norman E Breslow; Jeffrey Dome; Katherine Adams Guthrie; Pat Norkool; Sierra Li; Patrick R M Thomas; Elizabeth Perlman; J Bruce Beckwith; Giulio J D'Angio; Daniel M Green
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  DICER1 mutations in familial pleuropulmonary blastoma.

Authors:  D Ashley Hill; Jennifer Ivanovich; John R Priest; Christina A Gurnett; Louis P Dehner; David Desruisseau; Jason A Jarzembowski; Kathryn A Wikenheiser-Brokamp; Brian K Suarez; Alison J Whelan; Gretchen Williams; Dawn Bracamontes; Yoav Messinger; Paul J Goodfellow
Journal:  Science       Date:  2009-06-25       Impact factor: 47.728

8.  Dicer is essential for mouse development.

Authors:  Emily Bernstein; Sang Yong Kim; Michelle A Carmell; Elizabeth P Murchison; Heather Alcorn; Mamie Z Li; Alea A Mills; Stephen J Elledge; Kathryn V Anderson; Gregory J Hannon
Journal:  Nat Genet       Date:  2003-10-05       Impact factor: 38.330

9.  Risk perception after genetic counseling in patients with increased risk of cancer.

Authors:  Johanna Rantala; Ulla Platten; Gunilla Lindgren; Bo Nilsson; Brita Arver; Annika Lindblom; Yvonne Brandberg
Journal:  Hered Cancer Clin Pract       Date:  2009-08-23       Impact factor: 2.857

10.  Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.

Authors:  M Watson; C Foster; R Eeles; D Eccles; S Ashley; R Davidson; J Mackay; P J Morrison; P Hopwood; D G R Evans
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more
  4 in total

1.  Coffin-Siris Syndrome 4-Related Spectrum in a Young Woman Caused by a Heterozygous SMARCA4 Deletion Detected by High-Resolution aCGH.

Authors:  Anastasios Mitrakos; Leandros Lazaros; Amelia Pantou; Ariadni Mavrou; Emmanuel Kanavakis; Maria Tzetis
Journal:  Mol Syndromol       Date:  2020-06-13

2.  Cancer predisposing syndrome: a retrospective cohort analysis in a pediatric and multidisciplinary genetic cancer counseling unit.

Authors:  Adela Escudero; Cristina Ferreras; Nuria Rodriguez-Salas; Dolores Corral; Laura Rodriguez; Antonio Pérez-Martínez
Journal:  Int J Clin Oncol       Date:  2022-02-21       Impact factor: 3.402

3.  Optical genome mapping identifies a germline retrotransposon insertion in SMARCB1 in two siblings with atypical teratoid rhabdoid tumors.

Authors:  Mariangela Sabatella; Tuomo Mantere; Esmé Waanders; Kornelia Neveling; Arjen R Mensenkamp; Freerk van Dijk; Jayne Y Hehir-Kwa; Ronnie Derks; Michael Kwint; Luke O'Gorman; Madalena Tropa Martins; Corrie Em Gidding; Maarten H Lequin; Benno Küsters; Pieter Wesseling; Marcel Nelen; Jacklyn A Biegel; Alexander Hoischen; Marjolijn C Jongmans; Roland P Kuiper
Journal:  J Pathol       Date:  2021-07-29       Impact factor: 7.996

4.  Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group.

Authors:  Jette J Bakhuizen; Helen Hanson; Karin van der Tuin; Fiona Lalloo; Marc Tischkowitz; Karin Wadt; Marjolijn C J Jongmans
Journal:  Fam Cancer       Date:  2021-06-25       Impact factor: 2.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.